<?xml version="1.0" encoding="UTF-8"?>
<p>Prime-boost immunization strategies have been used for assessing vaccine candidates against several infectious agents. One of the most studied is the human immunodeficiency virus (HIV). Different types of prime-boost immunization regimens have been evaluated employing DNA, live viral vectors, and recombinant proteins [for recent and extensive reviews see (
 <xref rid="B8" ref-type="bibr">8</xref>, 
 <xref rid="B32" ref-type="bibr">32</xref>)]. Vaccine candidates against HCV, human papilloma virus (HPV) and Ebola virus, among others, have also been extensively evaluated in preclinical and clinical trials using complementary prime-boost immunization strategies (
 <xref rid="B8" ref-type="bibr">8</xref>).
</p>
